User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Congress Report: 27th European Meeting on Hypertension and Cardiovascular Protection (ESH)

Congress Report: 27th European Meeting on Hypertension and Cardiovascular Protection (ESH)
  • Cardiometabolic
  • Hypertension


Resource type



International meeting
combination therapy
drug adherence
resistant hypertension

Highlights from the 27th European Meeting on Hypertension and Cardiovascular Protection (ESH), Milan, Italy, June 16–19, 2017

The 2017 ESH meeting saw researchers and clinicians from more than 70 countries from all over the world converge in Milan. The ESH council and the Italian organizers constructed a well-balanced program covering 1500 abstracts in the 4-day meeting. In addition to the traditional oral and poster sessions, educational activities played an important role at this meeting, with plenary teaching sessions, as usual, drawing large audiences, but also featuring focused breakfast and topical workshops, meet-the-expert and ‘how-to’ sessions.

Several industry-sponsored symposia discussed new insights in diagnostic and therapeutic procedures in hypertension and cardiovascular protection.

            An important recurring topic was combination therapy. After a 30-year period of ‘stepped-care’ treatment of hypertension there is more and more evidence that (single pill) combinations of 2 or sometimes even 3 drugs are necessary for adequate blood pressure control in the majority of hypertensive patients. Whether this will lead ultimately to the “polypill” approach to cardiovascular risk reduction in hypertension remains a vigorously discussed, but as yet unresolved question.

A second topic covered in various sessions is poor drug adherence as a major cause of resistant hypertension. Although this phenomenon has been discussed already for many years, improved technical approaches to measure actual drug adherence have now firmly proven this notion. Non-adherence to medication and to non-pharmacological approaches to hypertension treatment negatively impacts hypertension control – the impact of this was discussed from many countries in various sessions.

Although no new major trials were presented at this meeting several new topics were introduced. One of these was the interventional treatment for fibromuscular and atherosclerotic renal artery stenosis. A second was the rapidly emerging new group of cancer survivors who, due to their anti-cancer treatment, sometimes develop severe forms of hypertension. Strategies how to recognize, follow-up and treat these patients were discussed in several presentations.

A traditional highlight of the ESH meetings is the award session. The most prestigious award of the ESH is the Bjorn Folkow lecture, which was given this year by Xavier Jeunemaitre (Paris, France) on his basic genetic research in endocrine forms of hypertension. Enrico Agabiti Rosei (Brescia, Italy) concluded his term as ESH president with a lecture on the assessment of cardiovascular damage in hypertension.

Terms of use

This is a copyrighted resource for the sole purpose of education. Resource may be used for classroom training only and must remain as is, including the branding and EXCEMED logo. It is backed by a publishing license, signed by the author.